Table 1.
Study population characteristic and demographics.
| Characteristics | mCRPC | PCa-l |
|---|---|---|
| Patient (n) | 12 | 16 |
| Median (range), years | 69 (53–72) | 63 (56–75) |
| Median (range) BMI | 27.5 (20.8–39) | 29.7 (22.5–34.5) |
| Median PSA (range), ng/mL at baseline | 25.6 (35–1200) | 8.2 (0.64–38.8) |
| Median PSA (range), ng/mL at the last visit | 44.95 (0.04–903) | 0,04 (0.04–0.06) |
| Median CRP (range), mg/mL | 7.3 (1.8–94.8) | 2.3 (1–26.2) |
| at baseline | ||
| Median HB (range), nmol/L | 7 (6.3–9.5) | 9.4 (7.9–10.5) |
| at baseline | ||
| Gleason sum, n (%) | ||
| ≤7 | 2 (16.67) | 11 (64.7) |
| >7 | 10 (83.33) | 6 (35.3) |
| Sites of metastasis, n (%) | ||
| Bone | 12 (100) | |
| Visceral | 4 (33.3) | |
| Nodal | 10 (83.3) | |
| Prior treatments, n (%) | ||
| TURP | 5 (41.7) | |
| Androgen treatment | 12 (100) | |
| Radiation | 9 (75) | |
| Treatments between baseline and study end, n (%) | ||
| TURP | ||
| Surgery (RP) | 14 (82.3) | |
| HIFU | 2 (11.8) | |
| Radiation | 10 (83.3) | |
| Bone-targeted therapy | 12 (100) | |
| Chemotherapy | ||
| Docetaxel | 10 (83.3) | |
| Cabazitaxel | 3 * (25) |
RP—radical prostatectomy; HB—hemoglobin; PSA—prostate-specific antigen; TURP—transurethral resection of the prostate; HIFU—high-intensity focused ultrasound; BMI—body mass index; CRP—C-reactive protein. 3 * one CRPC patient received docetaxel and switched to cabazitaxel during the study period.